Transplantation · 2017 · 26 citations · 29 references
MedicineOncologySurgeryCutaneous OncologyKidney TransplantationTransplant SurgeryKidney CancerNeoplastic Skin LesionsSkin Cancer Risk FactorsSkin TumorsSquamous Cell CarcinomaTransplant RejectionHigh-risk Cutaneous CarcinomaImmunosuppression-associated Skin CancerMalignancy Risk Under ImmunosuppressionSkin Cancer MortalitySkin Lesion Risk Stratification
BACKGROUND: The course of skin cancer after retransplantation in organ-transplant recipients who have already developed posttransplant skin cancer has not been assessed. METHODS: This retrospective multicentric study included 53 patients with a history of cutaneous squamous cell carcinoma (SCC) after a first kidney transplantation who received a second kidney transplantation. The primary endpoint was the occurrence of aggressive cutaneous SCC after the second transplantation. Secondary endpoints included the course of skin cancers over 3 periods (first transplantation, return to dialysis, second transplantation), the time to occurrence, and risk factors for aggressive SCC after retransplantation. RESULTS: The first SCC developed in 47 patients with a functional graft and in 6 after return to dialysis. After the first transplantation, 17 (33.3%) patients developed SCC in dialysis and 39 (73.6%) after the second transplantation, respectively. Twenty aggressive SCC developed over the study period. They occurred in 14 (26.4%) patients after retransplantation vs 5 (9.4%) after the first transplantation with a median delay of 50 months and were responsible for 5 deaths. Fair skin type, multiple tumors before retransplantation, treatment with azathioprine, T cell-depleting antibodies, and delayed revision of immunosuppression were associated with an increased risk of aggressive cutaneous SCC after retransplantation. CONCLUSIONS: Candidates to retransplantation with a history of posttransplant SCC have a high risk of aggressive SCC. Our data suggest that the risk could be reduced by a tailored immunosuppression. A wait period may be required depending on the clinicopathological characteristics of the previous SCC and discussed on an individual patient basis.
29
Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage
Peter O’Donovan, Conal M. Perrett, Xiaohong Zhang et al. · Science · 2005 · 631 citations · Full text
Medicine, Dermatology, Oncology +16
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard, Emmanuel Morélon, Lionel Rostaing et al. · New England Journal of Medicine · 2012 · 585 citations · Full text
Medicine, Dermatology, Oncology +17
Factors Predictive of Recurrence and Death From Cutaneous Squamous Cell Carcinoma
Chrysalyne D. Schmults, Pritesh S. Karia, Joi B. Carter et al. · JAMA Dermatology · 2013 · 569 citations